MIBELAS 24 FE
Clinical safety rating
cautionComprehensive clinical and safety monograph for MIBELAS 24 FE (MIBELAS 24 FE).
Combination hormonal contraceptive: ethinyl estradiol suppresses LH and FSH, primarily inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity, increasing cervical mucus viscosity and altering endometrial morphology.
| Metabolism | Ethinyl estradiol is extensively metabolized via CYP3A4; drospirenone is metabolized primarily via CYP3A4 with minor contribution from CYP1A1 and CYP2C9. |
| Excretion | Drospirenone: 40-50% renal as metabolites, <10% unchanged; ~50% fecal. Ethinyl estradiol: ~40% renal, 60% fecal. |
| Half-life | Drospirenone: ~30 hours; Ethinyl estradiol: ~17 hours. Steady-state reached after ~10 days for drospirenone. |
| Protein binding | Drospirenone: 95-97% bound to albumin; Ethinyl estradiol: ~97% bound to albumin, induces SHBG. |
| Volume of Distribution | Drospirenone: ~4 L/kg; Ethinyl estradiol: ~5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: Drospirenone ~76-85%; Ethinyl estradiol ~45% (due to first-pass metabolism). |
| Onset of Action | Inhibition of ovulation after 7 consecutive days of daily oral administration. |
| Duration of Action | 21 days of active pills provide cycle control; 7-day placebo interval allows withdrawal bleeding. |
| Molecular Weight | 310.5 |
One tablet orally once daily for 24 days followed by 4 placebo tablets. Each tablet contains 75 mcg desogestrel and 0.02 mg ethinyl estradiol.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended for mild to moderate renal impairment. Use with caution in severe renal impairment (GFR <30 mL/min) due to potential accumulation; consider alternative contraceptive methods. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment established. |
| Pediatric use | Approved for post-menarchal females. No weight-based dosing; same adult dose (one tablet daily) for adolescents. |
| Geriatric use | Not indicated for postmenopausal women. For women over 40 who need contraception, same adult dose is used if no contraindications; consider increased risk of thromboembolism, cardiovascular disease, and breast cancer. |
| 1st trimester | No data on safety in first trimester; combination oral contraceptives are not indicated during pregnancy. Avoid use in first trimester. |
| 2nd trimester | No data on safety in second trimester; combination oral contraceptives are not indicated during pregnancy. Avoid use in second trimester. |
| 3rd trimester | No data on safety in third trimester; combination oral contraceptives are not indicated during pregnancy. Avoid use in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for MIBELAS 24 FE (MIBELAS 24 FE).
| Placental transfer | Combination oral contraceptives are known to cross the placenta; animal studies show adverse effects, but human data is limited. Avoid use during pregnancy. |
| Breastfeeding | Combination hormonal contraceptives can reduce milk production and alter milk composition; use in breastfeeding women is generally not recommended until weaning. Small amounts of steroids pass into breast milk. |
| Lactation Rating | L4 (Possibly Hazardous) - limited data; may interfere with lactation. |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects due to progestin component. Second and third trimesters: potential for masculinization of female fetus from drospirenone (antiandrogenic activity) and estrogenic effects. Postnatal: possible long-term reproductive tract abnormalities. |
| Fetal Monitoring | Pregnancy test before initiation and at any missed period. Monitor for signs of pregnancy (nausea, breast tenderness, amenorrhea). If pregnancy suspected, discontinue immediately and confirm with ultrasound. No routine fetal monitoring recommended as drug is contraindicated. |
| Fertility Effects | Suppresses ovulation via combined hormonal contraception. Normal fertility returns upon discontinuation; no permanent impact on fertility. Rarely, may cause post-pill amenorrhea or anovulation (transient). |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, particularly in women over 35 years, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
| Serious Effects |
Known or suspected pregnancyThrombophlebitis or thromboembolic disordersCerebrovascular diseaseCoronary artery diseaseKnown or suspected breast cancerEstrogen-dependent neoplasiaHepatic adenoma or carcinomaActive liver diseaseUndiagnosed abnormal genital bleedingHypersensitivity to any component
| Precautions | Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction), Liver disease (hepatic adenoma, hepatocellular carcinoma), Elevated blood pressure, Gallbladder disease, Carbohydrate and lipid metabolism effects, Headache (including migraine), Menstrual irregularities (breakthrough bleeding, spotting, amenorrhea), Depression, Hereditary angioedema, Chloasma (melasma), Interactions with other drugs (e.g., anticonvulsants, St. John's wort) |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase estrogen exposure; limit consumption to 1-2 glasses per day. Iron from placebo tablets is better absorbed with vitamin C (e.g., orange juice) but avoid taking with dairy, calcium supplements, or antacids within 2 hours. |
| Clinical Pearls | MIBELAS 24 FE is a combination oral contraceptive containing drospirenone and ethinyl estradiol with ferrous fumarate placebo tablets. Drospirenone has antimineralocorticoid activity, which can cause hyperkalemia in patients with renal impairment, liver disease, or adrenal insufficiency. Monitor potassium levels in patients on concomitant ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics. The ferrous fumarate in the placebo tablets is not for therapeutic use; patients should not take additional iron unless directed. Advise patients that the placebo tablets are iron supplements. The 24/4 regimen (24 active + 4 placebo) may improve compliance. Contraindicated in women with migraine with aura, breast cancer, or liver tumors. |
| Patient Advice | Take one tablet daily at the same time, preferably in the evening, to minimize side effects. Missed doses increase pregnancy risk. · The last 4 tablets (green) are iron supplements and do not provide contraception. Do not skip them; take them to maintain the habit. · Use backup contraception (e.g., condoms) if you miss a dose, start late, or have vomiting/diarrhea. · Do not smoke while on this medication, especially if over 35, as it increases risk of blood clots. · Report signs of blood clots: leg pain/swelling, sudden shortness of breath, chest pain, or vision changes. · This medication does not protect against HIV or other STDs. · Tell your doctor about all medications, including herbal supplements (e.g., St. John's Wort) as they may reduce effectiveness. |
Loading safety data…